Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexey Boyko

Showing results (31-40 of 62) with videos related to

Pageof 7
Sort By:
Drug Design, Development and Therapy|July 16, 2016
Clinical implications for substandard, nonproprietary medicines in multiple sclerosis: focus on fingolimodJorge Correale, Erwin Chiquete, Alexey Boyko, et al.
Multiple Sclerosis and Related Disorders|December 26, 2021
Global transcriptome profiling in peripheral blood mononuclear cells identifies dysregulation of immune processes in individuals with radiologically isolated syndromeMaxim Kozin, Ivan Kiselev, Natalia Baulina, et al.
Multiple Sclerosis and Related Disorders|February 4, 2019
Genetic differences between primary progressive and relapsing-remitting multiple sclerosis: The impact of immune-related genes variabilityIvan Kiselev, Vitalina Bashinskaya, Natalia Baulina, et al.
Brain Sciences|September 19, 2020
Hyperhomocysteinemia and Endothelial Dysfunction in Multiple SclerosisEkaterina Dubchenko, Alexander Ivanov, Natalia Spirina, et al.
Multiple Sclerosis and Related Disorders|March 4, 2022
Genome-wide DNA methylation profiling identifies epigenetic changes in CD4+ and CD14+ cells of multiple sclerosis patientsIvan Kiselev, Ludmila Danilova, Natalia Baulina, et al.
Journal of the Neurological Sciences|March 23, 2016
Subcutaneous interferon β-1a in pediatric patients with multiple sclerosis: Regional differences in clinical features, disease management, and treatment outcomes in an international retrospective studyLauren B Krupp, Daniela Pohl, Angelo Ghezzi, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 10, 2016
Efficacy and safety of a three-times-weekly dosing regimen of glatiramer acetate in relapsing-remitting multiple sclerosis patients: 3-year results of the Glatiramer Acetate Low-Frequency Administration open-label extension studyOmar Khan, Peter Rieckmann, Alexey Boyko, et al.
Clinical Immunology (Orlando, Fla.)|July 8, 2011
Cladribine as a therapeutic option in multiple sclerosisClemens Warnke, Verena I Leussink, Norbert Goebels, et al.
Plos One|October 30, 2020
The influence of glatiramer acetate on Th17-immune response in multiple sclerosisMikhail Melnikov, Svetlana Sharanova, Anastasiya Sviridova, et al.
Pharmacogenomics|November 3, 2017
Pharmacogenetics of glatiramer acetate therapy for multiple sclerosis: the impact of genome-wide association studies identified disease risk lociOlga Kulakova, Vitalina Bashinskaya, Ivan Kiselev, et al.
Pageof 7

Showing results (31-40 of 62) with videos related to

Sort By:
Pageof 7
Drug Design, Development and Therapy|July 16, 2016
Clinical implications for substandard, nonproprietary medicines in multiple sclerosis: focus on fingolimodJorge Correale, Erwin Chiquete, Alexey Boyko, et al.
Multiple Sclerosis and Related Disorders|December 26, 2021
Global transcriptome profiling in peripheral blood mononuclear cells identifies dysregulation of immune processes in individuals with radiologically isolated syndromeMaxim Kozin, Ivan Kiselev, Natalia Baulina, et al.
Multiple Sclerosis and Related Disorders|February 4, 2019
Genetic differences between primary progressive and relapsing-remitting multiple sclerosis: The impact of immune-related genes variabilityIvan Kiselev, Vitalina Bashinskaya, Natalia Baulina, et al.
Brain Sciences|September 19, 2020
Hyperhomocysteinemia and Endothelial Dysfunction in Multiple SclerosisEkaterina Dubchenko, Alexander Ivanov, Natalia Spirina, et al.
Multiple Sclerosis and Related Disorders|March 4, 2022
Genome-wide DNA methylation profiling identifies epigenetic changes in CD4+ and CD14+ cells of multiple sclerosis patientsIvan Kiselev, Ludmila Danilova, Natalia Baulina, et al.
Journal of the Neurological Sciences|March 23, 2016
Subcutaneous interferon β-1a in pediatric patients with multiple sclerosis: Regional differences in clinical features, disease management, and treatment outcomes in an international retrospective studyLauren B Krupp, Daniela Pohl, Angelo Ghezzi, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 10, 2016
Efficacy and safety of a three-times-weekly dosing regimen of glatiramer acetate in relapsing-remitting multiple sclerosis patients: 3-year results of the Glatiramer Acetate Low-Frequency Administration open-label extension studyOmar Khan, Peter Rieckmann, Alexey Boyko, et al.
Clinical Immunology (Orlando, Fla.)|July 8, 2011
Cladribine as a therapeutic option in multiple sclerosisClemens Warnke, Verena I Leussink, Norbert Goebels, et al.
Plos One|October 30, 2020
The influence of glatiramer acetate on Th17-immune response in multiple sclerosisMikhail Melnikov, Svetlana Sharanova, Anastasiya Sviridova, et al.
Pharmacogenomics|November 3, 2017
Pharmacogenetics of glatiramer acetate therapy for multiple sclerosis: the impact of genome-wide association studies identified disease risk lociOlga Kulakova, Vitalina Bashinskaya, Ivan Kiselev, et al.
Pageof 7